Linked Life Data

11880733

Source:http://linkedlifedata.com/resource/pubmed/id/11880733

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2002-3-6
pubmed:abstractText
Hemophilic arthropathy occurs in all patients with severe and moderate hemophilia A and B in early adolescence after repeated bleeding in a major joint unless treated with replacement of the missing factor. Regular infusions of recombinant factor or treated plasma derived factor given prophylactically to prevent spontaneous bleeding are recommended for all children to maintain a plasma factor level of >1%. Recombinant factor product or treated plasma derived product should be used. Prophylaxis should begin when bleeding occurs repeatedly and is superior to on-demand therapy. Hypertrophied synovium should be removed surgically or with a sclerosing agent, either radioactive or chemical material, to impede further cartilaginous and bony deterioration. Arthroplasty of the knee and hip have been successful in reducing pain and loss of motion when other efforts to control synovial hypertrophy fail.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1040-8703
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
46-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Current treatment of hemophilic arthropathy.
pubmed:affiliation
Pediatric Hematology and Oncology, Weill Medical College of Cornell University, New York, New York 10021, USA. mah2015@med.cornell.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't